Academics, clinicians, and students worldwide can join our research community, the Genomics England Clinical Interpretations Partnership (GECIP, for short).
Research projects for Upper gastrointestinal cancer
Pancreatic cancer therapeutic response markers
Project Lead
William Greenhalf
Project Date
02/07/2020
Lay Summary
Patients with pancreatic cancer nearly always die of the disease, but some individuals can be cured (or at least given an extended period of healthy life) using a combination of surgery and specific drugs. Whilst some patients will benefit from a drug, others will not but will do well on another drug. We believe this is due to the pattern of altered DNA in the cancer cells and we are working with a company called Cellworks who have a way of identifying patterns of changed DNA. This may help better inform the initial choice of drug. This has been effective in other cancer types, but we would like to prove it also works for pancreatic cancer.
Patients with pancreatic cancer nearly always die of the disease, but some individuals can be cured (or at least given an extended period of healthy life) using a combination of surgery and specific drugs. Whilst some patients will benefit from a drug, others will not but will do well on another drug. We believe this is due to the pattern of altered DNA in the cancer cells and we are working with a company called Cellworks who have a way of identifying patterns of changed DNA. This may help better inform the initial choice of drug. This has been effective in other cancer types, but we would like to prove it also works for pancreatic cancer.
Integrative analysis of upper gastrointestinal cancers in the 100k cohort of Genomic England: from whole genomes to clinical management.
Project Lead
Gianmarco Contino
Project Date
05/05/2020
Lay Summary
Upper gastrointestinal tumours share poor outcomes and response to therapy. Integrating genomic data with clinical information is critical to identify genomic features that might inform clinical management and improve outcomes. We are performing a comprehensive analysis of the upper gastrointestinal cancer in the NGRL and integrate it with clinical data, outcomes and genomic tumour board reviews.
Upper gastrointestinal tumours share poor outcomes and response to therapy. Integrating genomic data with clinical information is critical to identify genomic features that might inform clinical management and improve outcomes. We are performing a comprehensive analysis of the upper gastrointestinal cancer in the NGRL and integrate it with clinical data, outcomes and genomic tumour board reviews.
The microbiome of upper GI cancer
Project Lead
Henry Wood
Project Date
20/12/2019
Lay Summary
The microbiome is the collection of bacteria, fungi and viruses living in an environment. We know that the microbiome is important within the gut, as certain “good bacteria” have been shown to be related to good health, whereas other “bad bacteria” may result in disease. We know that people who have a certain infection called Helicobacter pylori have a higher risk of developing stomach cancer. However, there is still a lot to understand in the field of the stomach and oesophageal microbiome and cancer. The aim of this investigation is to investigate whether the different make-up of the microbiome, or certain bacterial species of the microbiome, are linked to any clinically important features, with a view to developing a greater understanding of how the microbiome may affect of people with stomach and oesophagus cancer.
The microbiome is the collection of bacteria, fungi and viruses living in an environment. We know that the microbiome is important within the gut, as certain “good bacteria” have been shown to be related to good health, whereas other “bad bacteria” may result in disease. We know that people who have a certain infection called Helicobacter pylori have a higher risk of developing stomach cancer. However, there is still a lot to understand in the field of the stomach and oesophageal microbiome and cancer. The aim of this investigation is to investigate whether the different make-up of the microbiome, or certain bacterial species of the microbiome, are linked to any clinically important features, with a view to developing a greater understanding of how the microbiome may affect of people with stomach and oesophagus cancer.
Upper gastrointestinal cancer research plan
Full details of the research proposed by this domain
